Joaquin Duato - Johnson Johnson Chairman

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 35px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Chairman
Mr. Joaquin Boix Duato is the Vice Chairman Executive Committee of the Company
Age: 55  Chairman Since 2018      
732 214-0332  www.jnj.com
Duato joined the Company in 1989 with JanssenFarmaceutica S.A. and in 1997 became Managing Director of JanssenCilag S.p.A. . In 2000, he led Ortho Biotech Europe before relocating to the United States in 2002 to serve as Vice President, and, in 2005, President of Ortho Biotech Inc. In 2008, he was named Company Group Chairman, OrthoClinical Diagnostics, and in 2009, Company Group Chairman, Pharmaceuticals, where he oversaw pharmaceutical product launches and the major therapeutic franchises in Canada, the United States and Latin America. In 2011, he was named Worldwide Chairman, Pharmaceuticals, responsible for the global commercial businesses of the Janssen Pharmaceutical Companies, including functional support for the research & development organizations. In April 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals.

Joaquin Duato Latest Insider Activity

Joaquin Duato over three months ago via Macroaxis 
Johnson Johnson exotic insider transaction detected

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Daniel ODayGilead Sciences
2019
Joerg ReinhardtNovartis AG
2013
Giovanni CaforioBristol Myers Squibb Company
2017
Ian ReadPfizer
2018
Enrico VanniNovartis AG
2013
Daniel VasellaNovartis AG
N/A
Lamberto AndreottiBristol Myers Squibb Company
2015
Alex KrauerNovartis AG
N/A
Leif JohanssonAstrazeneca PLC
2012
John LechleiterEli Lilly And Company
2016
Paul BisaroAllergan Plc
2016
Ulrich LehnerNovartis AG
2006
Brenton SaundersAllergan Plc
2016
Kenneth FrazierMerck Company
2011
Moncef SlaouiGlaxoSmithKline PLC
2014
John MartinGilead Sciences
N/A

Entity Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 135100 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Director

Stock Performance Indicators

Did you try this?

Run Equity Search Now

   

Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also see Risk vs Return Analysis. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.